ELAHERE® (mirvetuximab soravtansine-gynx) for Injection, a …
WEBJan 19, 2024 · ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and
Elahere: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBMar 28, 2024 · Elahere (mirvetuximab soravtansine-gynx) is an injectable antibody-drug conjugate that may be used to treat adults with folate receptor-alpha (FRα) -positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have alr.
FDA approves mirvetuximab soravtansine-gynx (Elahere, …
WEBOn March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...
Mirvetuximab soravtansine - Wikipedia
WEBMirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [2][3] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. [3][4]
Elahere | European Medicines Agency (EMA)
WEB2 days ago · Elahere will be available as 5 mg/ml concentrate for solution for infusion. The active substance of Elahere is mirvetuximab soravtansine, an antineoplastic monoclonal antibody-drug conjugate (ATC code: L01FX26). Mirvetuximab is made up of an antibody that binds to the FRα receptor expressed on the surface of ovarian cancer cells and DM4, a ...
About ELAHERE | ELAHERE® (mirvetuximab soravtansine-gynx) …
WEBELAHERE is the first treatment for people with platinum-resistant ovarian cancer that targets FRα in order to deliver medicine inside the cell. Biomarkers may be genes, proteins, or other materials in a cell that can be tested and measured to …
FDA grants accelerated approval to mirvetuximab soravtansine …
WEBOn November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha...
Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
WEBApr 24, 2024 · Elahere is an antibody–drug conjugate made up of a monoclonal antibody called mirvetuximab attached to a highly potent chemotherapy drug called DM4. After being infused into patients, mirvetuximab seeks out and binds to FR-α on the surface of ovarian cancer cells.
AbbVie Receives Positive CHMP Opinion for Mirvetuximab …
WEB2 days ago · ELAHERE® (mirvetuximab soravtansine-gynx) U.S. INDICATION and IMPORTANT SAFETY INFORMATION ELAHERE® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive ...
AbbVie Receives Positive CHMP Opinion for Mirvetuximab
WEB2 days ago · ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis. Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including ...
Skip to content